Federal contractor profile

IMMUDEX USA, LLC

UEI TBNLHW1MFEJ1CAGE 63GQ8Company website ↗

Active

Small Business

Overview

Legal name: IMMUDEX USA, LLC
Registered location: FAIRFAX, VA, USA
Website: Company website ↗
Primary NAICS: 325413 — In-Vitro Diagnostic Substance Manufacturing
Latest award activity: Jul 22, 2026

Read company summary

IMMUDEX USA, LLC is associated with UEI TBNLHW1MFEJ1 and CAGE 63GQ8 in public federal records. AcornBids currently links 2 prime awards totaling $25.0K in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as In-Vitro Diagnostic Substance Manufacturing; Pharmaceutical Preparation Manufacturing. These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 325413 (In-Vitro Diagnostic Substance Manufacturing). Its public SAM.gov registration lists FAIRFAX, VA, USA.

At a glance

Lifetime prime obligations$25.0K

Prime awards2

Awards with future end dates1

Top-agency concentration100.0%

Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Sep 28, 2026. Refresh pending; these totals may be out of date.

Business information

Public SAM.gov registration details.

Legal name: IMMUDEX USA, LLC
UEI: TBNLHW1MFEJ1
CAGE: 63GQ8
Registered address: 10615 JUDICIAL DR STE 402, FAIRFAX, VA, 22030, USA
Registration status: Active
Primary NAICS: 325413 — In-Vitro Diagnostic Substance Manufacturing
SAM activation: Jul 30, 2026
Initial registration: Aug 9, 2010
Entity start: May 11, 2010
SAM updated: Jul 30, 2026
Registration expires: Jul 28, 2027
Fiscal year end: Jun 30
Place of incorporation: VA, USA

View SAM.gov source

Federal award analysis

Net transaction obligations by federal fiscal period.

Transaction history is not available in the loaded data. Annual funding is not estimated from current award totals.

Recent federal awards

Prime contract awards. Select an award to review its history and source evidence.

Award / description	Awarding agency	Obligations	Start date	End date
75N98026P01096NCI - CUSTOM MHC CLASS II HLA-DP XYNAPSE AND DEXTRAMER REAGENTS FOR LIVER CANCER NEOANTIGEN VALIDATION	Department of Health and Human Services	$25.0K	Jul 22, 2026	Jul 21, 2027
75N98025A00016O/M ITEMS ONLY: BLOOD/BLOOD PRODUCTS	Department of Health and Human Services	$10.0M	Oct 31, 2024	Not available

Explore, filter and export all awards →Subcontracts Grants & subgrants

Upcoming positioning windows

Modeled recompete windows are estimates, not announced solicitations or guarantees.

NCI - CUSTOM MHC CLASS II HLA-DP XYNAPSE AND DEXTRAMER REAGENTS FOR LIVER CANCER NEOANTIGEN VALIDATION

Department of Health and Human Services$25.0K obligationsEnds Jul 21, 202760% recompete estimate

Registration, certifications & contacts

Registration evidence	Date
SAM updated	Jul 30, 2026
Source loaded	Sep 26, 2026
Initial registration	Aug 9, 2010
Entity start	May 11, 2010

Registration classifications: Small Business. These are separate from the reported certificates above.

Industry	Reported size status
325413 — In-Vitro Diagnostic Substance Manufacturing	Not reported
325414 — Biological Product (except Diagnostic) Manufacturing	Not reported

Contact	Role	Published contact methods	Evidence	Source date
ALESSANDRA AUDIA	Government business	Contact method not published	SAM registration	Not available
PATRIK O DAHLEN	Electronic business	Contact method not published	SAM registration	Not available

Registered industries

325413 — In-Vitro Diagnostic Substance Manufacturing
325414 — Biological Product (except Diagnostic) Manufacturing

Registered products and services

6640 — Laboratory Equipment and Supplies

Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source